LitAlert ~~ GeneLit.com

    • Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    • Garufi G, Palazzo A, Paris I, Orlandi A, Cassano A, Tortora G, Scambia G, Bria E, Carbognin L.
    • Expert Opin Pharmacother. 2020 Feb 13:1-13. doi: 10.1080/14656566.2020.1724957. [Epub ahead of print]
    • Review
    • An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice—A Review.
    • Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O’Reilly EM.
    • JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.5963. [Epub ahead of print]
    • Review
    • BRCA2 and RB1 loss responds to PARP inhibitors.
    • Fenner A.
    • Nat Rev Urol. 2020 Feb 11. doi: 10.1038/s41585-020-0293-0. [Epub ahead of print]
    • Review
    • Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
    • Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V.
    • Support Care Cancer. 2020 Feb 11. doi: 10.1007/s00520-020-05320-4. [Epub ahead of print]
    • Guidelines
    • PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
    • Min A, Im SA.
    • Cancers (Basel). 2020 Feb 8;12(2). pii: E394. doi: 10.3390/cancers12020394.
    • Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
    • Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.
    • Oncologist. 2020 Feb;25(2):e198-e202. doi: 10.1634/theoncologist.2019-0603. Epub 2019 Oct 16.